Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Limited overlap in COVID infection risk and severity
Wed December 30th - The risk factors for COVID infection and severity of disease have "limited overlap," researchers report today. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Much ado as vaccination begins

Wednesday December 9th 2020

The Oxford university COVID-19 vaccine still lacks data on its effectiveness on adults over the age of 55, according to the first peer-reviewed analysis of the new vaccines.

The Lancet published the findings last night hours after the UK began the first routine vaccination programme against COVID-19 using the Pfizer mRNA vaccine.

The first vaccination was delivered in Coventry by a nurse May Parsons to Margaret Keenan, aged 90, and the second went to William Shakespeare.

Reports from individual hospitals suggested a number of ICU staff were included in yesterday’s vaccination programme. One of the first was senior sister Ly Fletcher in Walsall.

The Lancet report on the Oxford/Astrazeneca adenoviral vaccine involved 11,000 volunteers in the UK and Brazil. Just 12% were over the age of 55 and only five of these contracted the virus – making it impossible to reach conclusions about efficacy in this group.

Including volunteers from South Africa, researchers were able to report safety data from 23,000 participants with just three serious adverse incidents, one of them involving a recipient of placebo. The researchers say a case of severe fever in the vaccinated group but say it seemed to be an “expected vaccine-related event.”

The report confirms overall efficacy of 70.4% with 90% achieved in a UK-based trial group, representing nearly a third of the total participants and receiving and receiving a half dose in their first injection.

Professor Sarah Gilbert, from Oxford University, said: “We have known for many years that adenoviral vectored vaccines fulfil the requirements for use against outbreak or pandemic diseases. They are safe, highly immunogenic, can be manufactured in large quantities at low cost and do not require frozen storage.

“Following the demonstration of vaccine efficacy in many preclinical studies, we now have clear evidence of efficacy in the trial results presented in a peer-reviewed publication today. Now under regulatory review, we hope that this vaccine will shortly be in use to start saving lives.”

Dr Charlie Weller, head of vaccines at Wellcome, said it was “critically important” that the trial was completed.

Dr Weller said: “Although we await the trial completion and full data, it is highly encouraging to see the data behind the interim results announced last month, including an analysis of the different dosing regimens. This suggests that this vaccine could prevent asymptomatic disease.

“It’s important to remind ourselves that there are still important questions to be answered on the efficacy of this vaccine across different age groups and in different settings, which we will only be able to fully understand once Phase III is completed.

“The reassurance this published data provides is particularly welcome as the University of Oxford/AstraZeneca vaccine can be easily administered in existing healthcare systems around the world. It can be stored at fridge temperature and can use existing delivery mechanisms, giving it a distinct advantage for swift and successful global rollout.”

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 8 December 2020


Tags: Flu & Viruses | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)